*EMBARGOED All research presented at the 2024 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 27, 2024, at 12:00 pm ET.
Oral 52 – GLP-1 Receptor Agonists and Pancreatic Cancer Risk in Drug-Naive Patients With Type 2 Diabetes
Tuesday, October 29, 2024 | 3:15 PM – 3:25 PM ET | Terrace Ballroom 2-3
Author Insight from Khaled Alsabbagh Alchirazi, MD
What’s new here and important for clinicians?
GLP-1 receptor agonist medications are commonly prescribed to manage diabetes mellitus, and because their mechanism of action impacts the pancreas, it is important to investigate whether they could cause pancreatic cancer. In our study, there was no increased risk of pancreatic cancer. This was seen in both obese and non-obese diabetic patients.
What do patients need to know?
Although there were previous reports suggesting possible association between pancreatic cancer and GLP-1 receptor agonist medications, this study provides reassurance that there is no observed increased incidence of pancreatic cancer in patients prescribed these medications.
Author Contact
Khaled Alsabbagh Alchirazi, MD
Aurora Healthcare
Brookfield, WI
khaled.alsabb [at] gmail.com
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.